<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099966</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC 588</org_study_id>
    <nct_id>NCT04099966</nct_id>
  </id_info>
  <brief_title>AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitchell Cairo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing
      an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing
      α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients wiith selected malignant or non-malignant conditions meeting eligibility criteria
      will be enrolled on this study. Patients will receive one of either full intensity, reduced
      intensity, or reduced toxicity conditioning appropriate based on disease, disease status,
      organ function and performance status and will undergo α/β T-cell and CD 19+ B cell depleted
      alloSCT.

      Patients will be following for engraftment, chimerism, immune reconstitution, GVHD and QOL.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells</measure>
    <time_frame>1 year</time_frame>
    <description>patients will be monitored for any adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of hematpoitic engraftment following Allogeneic stem cell transplantation (AlloSCT) utilizing α/β CD3+/CD19+ cell depletion</measure>
    <time_frame>1 year</time_frame>
    <description>patients will have routine chimerism performed to monitoring engraftment of donor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of GVHD following Allogeneic stem cell transplantation (AlloSCT) utilizing α/β CD3+/CD19+ cell depletion</measure>
    <time_frame>1 year</time_frame>
    <description>patients will be monitored post transplant for signs of acute and chronic GVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Kostmann</condition>
  <condition>Diamond Blackfan Anemia</condition>
  <condition>Amegakaryocytic Thrombocytopenia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>alpha beta cell depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha beta depletion</intervention_name>
    <description>donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.</description>
    <arm_group_label>alpha beta cell depletion</arm_group_label>
    <other_name>α/β CD3+/CD19+ cell depletion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ALL:ALL high risk including one or more of the following: (t(9;22) or 11q23
             chromosomal abnormality, primary induction failure (&lt;15% blasts at time of
             registration), mixed phenotype acute leukemia (MPAL), persistent MRD (&lt;0.01% by flow
             or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (44
             chromosomes)) in first remission ' ALL in second remission and beyond;

          2. AML: History of AML induction/reinduction Failure (&lt;15% blasts at time of
             registration); AML in CR1 with poor cytogenetics (i.e. 12p, 5a, -7, FLT3
             mutation/duplication, t(9;11) and others); AML with persistent minimal residual
             disease (MRD) in CR1(&lt;0.01% on flow or persistent abnormal karyotype detected by
             cytogenetics); AML CR2 or beyond; AML in refractory relapse but ≤15% bone marrow
             leukemia blasts; Therapy-related AML

          3. High Risk Myelodysplastic syndrome (MDS) 4 Lymphoma: Hodgkin (HL) or Non-Hodgkin
             (NHL): HL or NHL in induction failure; HL or NHL in PR1 or PR2 ; HL or NHL in CR2 or
             subsequent remission

        5. Bone marrow failure syndromes: Kostmann syndrome refractory or intolerant to granulocyte
        colony-33stimulating factor; Diamond-Blackfan anemia refractory or intolerant to
        corticosteroids and/or cyclosporine'; amegakaryocytic thrombocytopenia 6. Sickle Cell
        Disease (Homozygous Hemoglobin S Disease, or Hemoglobin S β 0/+ thalassemia, or Hemoglobin
        SC Disease) 7. age 0-30 years 8. adequate organ function

        Exclusion Criteria:

          1. Females who are pregnant or breast-feeding are not eligible.

          2. Patients with documented uncontrolled infection at the time of study entry are not
             eligible.

          3. Karnofsky/Lansky (age appropriate) Performance Score &lt;60

          4. Demonstrated lack of compliance with medical care

          5. Patients who have received allogeneic HSCT within 6 months, unless being done as a
             boost.

          6. Patients with active &lt;Grade 2 GVHD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo</last_name>
    <role>Study Chair</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell S Cairo, MD</last_name>
    <phone>9145942150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Harrison, RN</last_name>
    <phone>6172857844</phone>
    <email>lauren_harrison@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Co-Investgiator</investigator_title>
  </responsible_party>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>t-cell depletion</keyword>
  <keyword>alpha beta cell depletion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

